Linaclotide (Constella®) is recommended as an option for restricted use within NHS Wales. Linaclotide (Constella®) should be restricted for use in the following subpopulation within its licensed indication for the symptomatic treatment of moderate to severe irritable bowel syndrome (IBS) with constipation in adults:

• Patients who have not responded adequately to or cannot tolerate antispasmodics and/or laxatives.

Linaclotide (Constella®) is not recommended for use within NHS Wales outside of this subpopulation.